More importantly, few studies evaluating the systemic inflammation/nutritional status addressed the issue of the treatment choice in patients suffering from an NSCLC with PD-L1 TPS ≥50%, as these can be treated either with ICI in monotherapy or with ICI + CT [18]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.